Scott Rocklage is a chemist with a Bachelor of Science (BS) degree in Chemistry from the University of California and a Doctor of Philosophy (PhD) in Chemistry from the Massachusetts Institute of Technology (MIT).
Dr. Rocklage is currently the managing partner of 5AM Ventures. He brings to the role more than 30 years of healthcare management. He has experience in strategic leadership that has led to Food and Drug Administration (FDA) approval of three recently new drug applications.
5AM Ventures is a venture capital firm that focuses on building next-generation life science opportunities. 5AM supports entities that are working to solve needs in healthcare through a combination of cutting-edge science and medicine. The companies supported through 5AM Ventures are those that take an unusual or unorthodox approach to healthcare solutions with strategic thinking. Read more: Scott Racklage | Bloomberg
Dr. Rocklage leads a team of professionals at 5AM Ventures that are made up of financial, legal, operational and medical individuals that work together, combining all their talents and expertise to give the team a unique edge in the healthcare industry. In addition to being an investor, 5M also takes hands on approach to building a company. 5AM often works to help set company strategy, fundraising, business development and recruiting.
Dr. Rocklage has taken on employment opportunities with a variety of Pharmaceutical companies and includes Cubist Pharmaceuticals, Nycomed Salutar and Catalytica. He has served these companies in a variety of positions including President, Chief Executive Officer (CEO), Chairman and Research and Design (R&D) specialist.
Scott Rocklage is responsible as an inventor and co-inventor of more than 30 U.S. patents and he has authored more than 100 peer-reviewed publications. Also to his credit, Rocklage conducted research in the laboratory of Richard R. Scrock, who went on to win the Nobel Peace Prize in Chemistry in 2005, while Rocklage was a student at MIT.
Rocklage also serves as the Chairman of the Board for Achaogen, Relypsa and Sempura. He also sits on the boards of Variation, Pulmatrix and WaveRx, as well as the Board of Associates of the Whitehead Institute. He was also the Executive Chairman of the Board of Iilypsa